The role of FOXP3 in non-small cell lung cancer and its therapeutic potentials.

Pharmacol Ther

Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China; Department of Otorhinolaryngology, Head and Neck Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China. Electronic address:

Published: January 2023

Although in the last few decades we have witnessed the rapid development of treatments for non-small cell lung cancer (NSCLC), it still remains the leading cause of cancer-related death. Increasing efforts have been devoted to exploring potential biomarkers and molecular targets for NSCLC. Foxp3, a transcription factor that was discovered as a master regulator of regulatory T cells (Tregs), has been found to express abnormally in tumoral cells including lung cancer cells. In recent years, increasing evidence have surfaced, revealing the carcinogenic effect of FOXP3 in lung cancer. In this review, we analyzed and summarized the function of FOXP3, its regulation and therapeutic potentials in NSCLC, with a hope to facilitate the development of novel treatments for NSCLC.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharmthera.2022.108333DOI Listing

Publication Analysis

Top Keywords

lung cancer
16
non-small cell
8
cell lung
8
therapeutic potentials
8
role foxp3
4
foxp3 non-small
4
lung
4
cancer
4
cancer therapeutic
4
potentials decades
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!